Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bemcentinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BerGenBio Announces Data Indicating Broadened Potential for Bemcentinib
    BerGenBio Announces Data Indicating Broadened Potential for Bemcentinib

    07 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-announces-new-preclinical-data-indicating-broadened-potential-for-bemcentinib-to-treat-severe-respiratory-infections-302055930.html

    PR NEWSWIRE
    07 Feb 2024
    Share Share
    Data on BerGenBio's selective AXL inhibitor bemcentinib to be presented
    Data on BerGenBio's selective AXL inhibitor bemcentinib to be presented

    16 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/additional-data-on-bergenbios-selective-axl-inhibitor-bemcentinib-to-be-presented-at-the-2023-esmo-meeting-301957048.html

    PR NEWSWIRE
    16 Oct 2023
    Share Share
    BerGenBio announces data presentations showing activity of bemcentinib in NSCLC
    BerGenBio announces data presentations showing activity of bemcentinib in NSCLC

    22 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-announces-clinical-data-presentations-highlighting-the-activity-of-its-selective-axl-inhibitor-bemcentinib-in-non-small-cell-lung-cancer-301906548.html

    PR NEWSWIRE
    22 Aug 2023
    Share Share
    BerGenBio Announces First Patient Dosed in Ph1b/2a Trial Evaluating Bemcentinib
    BerGenBio Announces First Patient Dosed in Ph1b/2a Trial Evaluating Bemcentinib

    09 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-announces-first-patient-dosed-in-phase-1b2a-trial-evaluating-bemcentinib-in-1st-line-non-small-cell-lung-cancer-with-stk11-mutations-301767796.html

    PR NEWSWIRE
    09 Mar 2023
    Share Share
    BerGenBio randomises first patient in Covid-19 treatment study
    BerGenBio randomises first patient in Covid-19 treatment study

    28 Sep 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/bergenbio-covid-treatment-study/

    CLINICALTRIALSARENA
    28 Sep 2022
    Share Share
    BerGenBio, Oslo University's Bemcentinib will be Studied in EU-SolidAct trial
    BerGenBio, Oslo University's Bemcentinib will be Studied in EU-SolidAct trial

    27 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-and-oslo-university-hospital-announce-the-axl-inhibitor-bemcentinib-will-be-studied-in-the-eu-funded-eu-solidact-trial-in-hospitalised-covid-19-patients-301469371.html

    PRNEWSWIRE
    27 Jan 2022
    Share Share